{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:41:09Z","timestamp":1761514869652,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bpobgyn.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T03:21:48Z","timestamp":1644981708000},"page":"188-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"PB","title":["Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry"],"prefix":"10.1016","volume":"85","author":[{"given":"Klaus","family":"B\u00fchler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Enrique","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Lispi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Allignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edel","family":"Falla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasily","family":"Lukyanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"D\u00b4Hooghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2022.02.002_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The development of gonadotropins for clinical use in the treatment of infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.02.002_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.fertnstert.2018.06.005","article-title":"Forty years of IVF","volume":"110","author":"Niederberger","year":"2018","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00063030-199809030-00006","article-title":"Follitropin alpha in infertility: a review","volume":"9","author":"Goa","year":"1998","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1472-6483(10)60163-0","article-title":"Analytical identification of additional impurities in urinary-derived gonadotrophins","volume":"19","author":"Bassett","year":"2009","journal-title":"Reprod Biomed Online"},{"year":"2004","series-title":"Fertility: assessment and treatment for people with fertility problems. clinical guideline","author":"Ncc-Wch","key":"10.1016\/j.bpobgyn.2022.02.002_bib5"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.02.002_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/humrep\/deg088","article-title":"Meta-analysis of recombinant versus urinary-derived FSH: an update","volume":"18","author":"Al-Inany","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib7","series-title":"Recombinant FSH as adjuvant in assisted reproduction: some data on the efficacy and efficiency of recombinant FSH urinary FSH","first-page":"1","author":"Larizgoitia","year":"2000"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib8","doi-asserted-by":"crossref","first-page":"hoz008","DOI":"10.1093\/hropen\/hoz008","article-title":"Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis","volume":"2019","author":"Bordewijk","year":"2019","journal-title":"Hum Reprod Open"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.02.002_bib9","article-title":"Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles","author":"van Wely","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.02.002_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1472-6483(10)60559-7","article-title":"Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis","volume":"16","author":"Al-Inany","year":"2008","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.02.002_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/humrep\/dem305","article-title":"Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis","volume":"23","author":"Coomarasamy","year":"2008","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.02.002_bib12","article-title":"Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles","author":"Van Wely","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.02.002_bib13","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fertnstert.2020.03.029","article-title":"Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection","volume":"114","author":"Witz","year":"2020","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.02.002_bib15","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbmo.2016.11.010","article-title":"Model\u2019 versus \u2018everyday\u2019 patients: can randomized controlled trial data really be applied to the clinic?","volume":"34","author":"Hershkop","year":"2017","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.02.002_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"issue":"149","key":"10.1016\/j.bpobgyn.2022.02.002_bib18","doi-asserted-by":"crossref","first-page":"180080","DOI":"10.1183\/16000617.0080-2018","article-title":"Randomised controlled trials and real-life studies: two answers for one question","volume":"27","author":"Harari","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.bpobgyn.2022.02.002_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40258-016-0259-9","article-title":"Economic evaluation of three frequently used gonadotrophins in assisted reproduction techniques in the management of infertility in The Netherlands","volume":"14","author":"Fragoulakis","year":"2016","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J\u00a0Multidiscip Healthc"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.02.002_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rbmo.2017.10.102","article-title":"Does ovarian stimulation regimen affect IVF outcome? a two-centre, real-world retrospective study using predominantly cleavage-stage, single embryo transfer","volume":"36","author":"Karlstr\u00f6m","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1477-7827-8-137","article-title":"In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review","volume":"8","author":"Trew","year":"2010","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.02.002_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12958-021-00768-3","article-title":"Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany","volume":"19","author":"B\u00fchler","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/humrep\/dev336","article-title":"Cumulative live birth rates after one or more complete cycles of IVF: a population-based study of linked cycle data from 178 898 women","volume":"31","author":"McLernon","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.fertnstert.2014.05.020","article-title":"A prediction model for live birth and multiple births within the first three cycles of assisted reproductive technology","volume":"102","author":"Luke","year":"2014","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.02.002_bib26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1472-6483(10)60380-X","article-title":"An economic evaluation of highly purified HMG and recombinant FSH based on a large randomized trial","volume":"15","author":"Wechowski","year":"2007","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"10.1016\/j.bpobgyn.2022.02.002_bib27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.fertnstert.2008.01.034","article-title":"Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha","volume":"91","author":"Wechowski","year":"2009","journal-title":"Fertil Steril"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.02.002_bib28","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/humrep\/16.12.2557","article-title":"The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments","volume":"16","author":"Sykes","year":"2001","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.bpobgyn.2022.02.002_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.rbmo.2010.05.005","article-title":"HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: success rates and economic evaluation","volume":"21","author":"Wex-Wechowski","year":"2010","journal-title":"Reprod Biomed Online"},{"issue":"9","key":"10.1016\/j.bpobgyn.2022.02.002_bib30","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/humrep\/dem221","article-title":"Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF","volume":"22","author":"Ziebe","year":"2007","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.bpobgyn.2022.02.002_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40258-017-0361-7","article-title":"Cost-effectiveness analysis of the gonadotropin treatments HP-hMG and rFSH for assisted reproductive technology in France: a markov model analysis","volume":"16","author":"Barriere","year":"2018","journal-title":"Appl Health Econ Health Pol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2022.02.002_bib32","doi-asserted-by":"crossref","first-page":"A522","DOI":"10.1016\/j.jval.2017.08.700","article-title":"The cost-effectiveness of IVF treatments gonal-F\u00ae versus HP-HMG in the United Arab Emirates (UAE)","volume":"20","author":"Elkalyoubi","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib33","first-page":"196","article-title":"D.I.R. Annual 2019","volume":"17","author":"Blumenauer","year":"2020","journal-title":"J\u00a0Reprod Med Endocrinol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2022.02.002_bib34","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/humrep\/deab040","article-title":"Patient willingness, preferences and decision-making about planning for three complete cycles of IVF\/ICSI treatment","volume":"36","author":"Harrison","year":"2021","journal-title":"Hum Reprod"},{"year":"2020","key":"10.1016\/j.bpobgyn.2022.02.002_bib35"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib36","unstructured":"Lauer-Fischer GmbH. WEBAPO\u00ae T InfoSystem 2020 [Accessed 21 Sep 2021]."},{"year":"2003","series-title":"Making choices in health: WHO guide to cost effectiveness analysis Geneva","author":"World Health Organization","key":"10.1016\/j.bpobgyn.2022.02.002_bib37"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib38","doi-asserted-by":"crossref","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"McDougall","year":"2020","journal-title":"JMAHP"},{"year":"2021","series-title":"GDP per capita (current LCU) - Germany","author":"Bank","key":"10.1016\/j.bpobgyn.2022.02.002_bib39"},{"issue":"6","key":"10.1016\/j.bpobgyn.2022.02.002_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/0962280211419832","article-title":"Probabilistic sensitivity analysis in health economics","volume":"24","author":"Baio","year":"2015","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.bpobgyn.2022.02.002_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejogrb.2018.04.006","article-title":"Treatment strategies and cumulative live birth rates in WHO-II ovulation disorders","volume":"225","author":"Braam","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa0803072","article-title":"Cumulative live-birth rates after in\u00a0vitro fertilization","volume":"360","author":"Malizia","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.bpobgyn.2022.02.002_bib43","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/humrep\/deh501","article-title":"What is the most relevant standard of success in assisted reproduction?: the cumulated singleton\/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA","volume":"19","author":"Germond","year":"2004","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.bpobgyn.2022.02.002_bib44","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.fertnstert.2014.08.002","article-title":"Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement","volume":"102","year":"2014","journal-title":"Fertil Steril"},{"issue":"12","key":"10.1016\/j.bpobgyn.2022.02.002_bib45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","article-title":"Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models","volume":"36","author":"Hatswell","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0015-0282(02)03250-8","article-title":"Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in\u00a0vitro fertilization\/intracytoplasmic sperm injection cycles: a randomized, comparative trial","volume":"78","year":"2002","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.bpobgyn.2022.02.002_bib47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","article-title":"A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer","volume":"97","author":"Devroey","year":"2012","journal-title":"Fertil Steril"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693422000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:15:09Z","timestamp":1761498909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693422000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":47,"alternative-id":["S1521693422000244"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.02.002","relation":{},"ISSN":["1521-6934"],"issn-type":[{"type":"print","value":"1521-6934"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}